Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239161 | 0.89 | POLB (0.46) | UTS2RPOLBSMN1; SMN2HRH3CSNK2A1 | |
| SCHEMBL12239160 | 0.87 | POLB (0.44) | POLBSMN1; SMN2HRH3CSNK2A1SCN1A | |
| SCHEMBL1006218 | 0.87 | UTS2R (0.46) | UTS2RGPR119TBK1SCN1ASCN8A | |
| SCHEMBL12239172 | 0.86 | SMN1; SMN2 (0.43) | UTS2RPOLBSMN1; SMN2HRH3CSNK2A1 | |
| SCHEMBL12239159 | 0.86 | SCD (0.49) | POLBSMN1; SMN2CSNK2A1SCN1ASCN8A | |
| SCHEMBL12239164 | 0.84 | HRH1 (0.44) | UTS2RSCD | |
| SCHEMBL12239163 | 0.83 | OPRK1 (0.43) | UTS2RPOLBSMN1; SMN2HRH3CSNK2A1 | |
| SCHEMBL12239158 | 0.81 | UTS2R (0.45) | UTS2RSCN1ASCN8A | |
| SCHEMBL12239165 | 0.81 | DGAT2 (0.48) | UTS2RSCN1ASCN8A | |
| SCHEMBL1007986 | 0.80 | UTS2R (0.41) | UTS2RSMN1; SMN2GPR119TBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR55, NR1H2 | UTS2R 265/4885POLB 4770/4885SMN1; SMN2 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.